ID

28126

Descripción

Study ID: 101468/125 Clinical Study ID: SKF-101468/125 Study Title: A double-blind, multicentre, flexible dose, L-dopa controlled study of ropinirole to investigate A) neuroprotective effect as measured by 3D PET scanning, and B) ophthalmological safety, in patients with early Parkinson’s disease Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: requip

Palabras clave

  1. 20/12/17 20/12/17 -
Titular de derechos de autor

GlaxoSmithKline

Subido en

20 de diciembre de 2017

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

L-dopa controlled study of ropinirole, neuroprotective effect and ophthalmological safety in early Parkinson’s disease 101468/125

Module 3 Visit 6 Month 6

Current Dose Level
Descripción

Current Dose Level

Record the dose level that the patient is currently taking
Descripción

Current Dose Level

Tipo de datos

text

Vital signs
Descripción

Vital signs

Sitting blood pressure (systolic)
Descripción

Sitting blood pressure (systolic)

Tipo de datos

integer

Unidades de medida
  • mmHg
mmHg
Sitting blood pressure (diastolic)
Descripción

Sitting blood pressure (diastolic)

Tipo de datos

integer

Unidades de medida
  • mmHg
mmHg
Sitting Heart Rate
Descripción

Sitting Heart Rate

Tipo de datos

integer

Unidades de medida
  • beats/min
beats/min
Concomitant Medication
Descripción

Concomitant Medication

Concomitant Medication
Descripción

Transcribe any ongoing concomitant medications from the previous module, and record any change in the patient´s concomitant medication since the last visit in the Concomitant Medication section towards the back of this module.

Tipo de datos

text

Adverse Experiences
Descripción

Adverse Experiences

Adverse Experiences
Descripción

Have there been any adverse experiences observed or elicited by the following direct question to the patient: "Have you felt different in any way since your last visit?" Transcribe any ongoing adverse experiences from the previous module, record any changes to ongoing adverse experiences, and details of any new adverse experiences observed or reported by the patient in the Adverse Experiences section towards the back of this module.

Tipo de datos

text

L-Dopa Rescue
Descripción

L-Dopa Rescue

L-Dopa Rescue
Descripción

Patients must complete as a minimum the initial titration to dose level 5. Titration of the dose of study medication to the maximum tolerated dose is encouraged. However if the patients symptoms remain inadequately controlled, open label L-dopa may be prescribed as rescue medication. Transcribe any ongoing L-dopa medication from the previous module, record any changes in L-dopa since the last visit, and details of any L-dopa that the patient has started, or is about to start taking, in the L-dopa Rescue section towards the back of this module.

Tipo de datos

text

Study Medication Compliance
Descripción

Study Medication Compliance

Has the patient been compliant with study medication? (compliance is defined as taking between approximately 80%-120% of medication)
Descripción

Study Medication Compliance

Tipo de datos

integer

End of visit instructions for patients continuing
Descripción

End of visit instructions for patients continuing

Schedule the patient´s next visit to the ISCEV centre for their second ERG examination.
Descripción

NB. this visit must take place at least 6 months after the initial ERG examination. • Tear-out the patient's appointment card (next page) and record the date and time of the appointment and your centre number on the card. If the date and time of the patient's second ERG examination is not yet known, please remember to inform the patient of this information when it becomes available. • lnstruct the patient that they must take their appointment card to their ERG examination visit. • Depending on the dose level that the patient is to take from today, order the second 6 month supply of medication for the patient. • Arrange for the patient to return for their next clinic visit in six months time. • Complete the Patient Continuation/Withdrawal section at the back of this module.

Tipo de datos

date

End of visit instructions for patients not continuing
Descripción

End of visit instructions for patients not continuing

Complete the Patient Continuation/Withdrawal section at the back of this module.
Descripción

End of visit instructions for patients not continuing

Tipo de datos

text

ERG Examintion Appointment Card
Descripción

ERG Examintion Appointment Card

Patient Number
Descripción

Patient Number

Tipo de datos

integer

Patient Initials
Descripción

Patient Initials

Tipo de datos

text

Centre Number
Descripción

Centre Number

Tipo de datos

integer

ERG Examination Visit Date and Time
Descripción

ERG Examination Visit Date and Time

Tipo de datos

datetime

Doctor´s Contact Number
Descripción

Doctor´s Contact Number

Tipo de datos

text

Concomitant Medication
Descripción

Concomitant Medication

Concomitant Medication
Descripción

Transcribe any ongoing concomitant medication from the previous module, and record any concomitant medication changes since the last visit. Any new medical illness/diagnosis or symptoms in the absence of a diagnosis should be recorded in the Adverse Experience section utilising the same terminology. If a medication was marked "Continuing" at the last visit, but has since had a dosage change or has been stopped, it must be recorded as a change with the start and end date. If no concomitant medication answer question appropriately.

Tipo de datos

boolean

Details on concomitant medication
Descripción

Details on concomitant medication

Drug Name (Trade Name preferred)
Descripción

Drug Name

Tipo de datos

text

Total daily dose
Descripción

Total daily dose

Tipo de datos

float

Unidades de medida
  • mg
mg
Medical condition
Descripción

Medical condition

Tipo de datos

text

Approximate Start Date
Descripción

Approximate Start Date

Tipo de datos

date

End Date
Descripción

End Date

Tipo de datos

date

For SB
Descripción

For SB

Tipo de datos

text

Levodopa Rescue Therapy
Descripción

Levodopa Rescue Therapy

Has the patient started to take, has there been any change in or, is there any ongoing L-dopa rescue?
Descripción

Levodopa Rescue Therapy

Tipo de datos

text

Primary reason for rescue
Descripción

Primary reason for rescue

Tipo de datos

text

Details on Levodopa - rescue therapy
Descripción

Details on Levodopa - rescue therapy

Start Date
Descripción

Start Date

Tipo de datos

date

End Date
Descripción

End Date

Tipo de datos

date

Total Daily L-dopa Dose
Descripción

Total Daily L-dopa Dose

Tipo de datos

float

Unidades de medida
  • mg
mg
Proprietary Preparation
Descripción

Proprietary Preparation

Tipo de datos

text

Adverse Experiences
Descripción

Adverse Experiences

Have there been ongoing adverse experiences at the last visit and no adverse experiences occured since?
Descripción

Ongoing adverse Experiences

Tipo de datos

boolean

Details on Adverse Experiences
Descripción

Details on Adverse Experiences

Experience
Descripción

Experience

Tipo de datos

text

For SB
Descripción

For SB

Tipo de datos

text

Date Started
Descripción

Date Started

Tipo de datos

date

Date Stopped
Descripción

Date Stopped

Tipo de datos

date

Duration if less than 24hrs
Descripción

Duration if less than 24hrs

Tipo de datos

float

Unidades de medida
  • hrs
hrs
Experience continuing?
Descripción

Experience continuing?

Tipo de datos

boolean

Course Continuation
Descripción

Course Continuation

Tipo de datos

boolean

If not continuing no. of episodes
Descripción

If not continuing no. of episodes

Tipo de datos

integer

Intensity
Descripción

Intensity

Tipo de datos

integer

Aktion taken on Study Medication
Descripción

Aktion taken on Study Medication

Tipo de datos

text

Suspected Relationship
Descripción

Suspected Relationship

Tipo de datos

integer

Corrective Therapy
Descripción

Corrective Therapy

Tipo de datos

text

Do you consider this a serious adverse experience by the definitions on the tab?
Descripción

Serious Adverse Experience

Tipo de datos

boolean

AEGIS
Descripción

AEGIS

Tipo de datos

text

Investigator´s Signature
Descripción

Investigator´s Signature

Investigator´s Signature
Descripción

Investigator´s Signature

Tipo de datos

text

Date
Descripción

Date

Tipo de datos

date

Patient Continuation / Withdrawal
Descripción

Patient Continuation / Withdrawal

Is the patient continuing in the study?
Descripción

Is the patient continuing in the study?

Tipo de datos

integer

Specification of reason for withdrawal
Descripción

Specification of reason for withdrawal

Tipo de datos

integer

If Other reason for withdrawal, please specify
Descripción

Specification of other reason for withdrawal

Tipo de datos

text

Date of last dose
Descripción

Date of last dose

Tipo de datos

date

Investigator´s Signature
Descripción

Investigator´s Signature

Investigator´s Signature
Descripción

I certify that I have reviewed the data in this module and that all the information is complete and accurate.

Tipo de datos

text

Date
Descripción

Date

Tipo de datos

date

Similar models

Module 3 Visit 6 Month 6

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Current Dose Level
Current Dose Level
Item
Record the dose level that the patient is currently taking
text
Item Group
Vital signs
Sitting blood pressure (systolic)
Item
Sitting blood pressure (systolic)
integer
Sitting blood pressure (diastolic)
Item
Sitting blood pressure (diastolic)
integer
Sitting Heart Rate
Item
Sitting Heart Rate
integer
Item Group
Concomitant Medication
Concomitant Medication
Item
Concomitant Medication
text
Item Group
Adverse Experiences
Adverse Experiences
Item
Adverse Experiences
text
Item Group
L-Dopa Rescue
L-Dopa Rescue
Item
L-Dopa Rescue
text
Item Group
Study Medication Compliance
Item
Has the patient been compliant with study medication? (compliance is defined as taking between approximately 80%-120% of medication)
integer
Code List
Has the patient been compliant with study medication? (compliance is defined as taking between approximately 80%-120% of medication)
CL Item
No -> If "No" consider withdrawing the patient if they have been non-compliant with study medication on two consecutive visits.  (1)
CL Item
Yes (2)
Item Group
End of visit instructions for patients continuing
Date of scheduled ERG exam
Item
Schedule the patient´s next visit to the ISCEV centre for their second ERG examination.
date
Item Group
End of visit instructions for patients not continuing
End of visit instructions for patients not continuing
Item
Complete the Patient Continuation/Withdrawal section at the back of this module.
text
Item Group
ERG Examintion Appointment Card
Patient Number
Item
Patient Number
integer
Patient Initials
Item
Patient Initials
text
Centre Number
Item
Centre Number
integer
ERG Examination Visit Date and Time
Item
datetime
Doctor´s Contact Number
Item
Doctor´s Contact Number
text
Item Group
Concomitant Medication
Concomitant Medication
Item
Concomitant Medication
boolean
Item Group
Details on concomitant medication
Drug Name
Item
Drug Name (Trade Name preferred)
text
Total daily dose
Item
Total daily dose
float
Medical condition
Item
Medical condition
text
Approximate Start Date
Item
Approximate Start Date
date
End Date
Item
End Date
date
For SB
Item
For SB
text
Item Group
Levodopa Rescue Therapy
Item
Has the patient started to take, has there been any change in or, is there any ongoing L-dopa rescue?
text
Code List
Has the patient started to take, has there been any change in or, is there any ongoing L-dopa rescue?
CL Item
No (1)
CL Item
Yes -> If "Yes" record details below, if this is the first rescue specify primary reason below. (2)
Item
Primary reason for rescue
text
Code List
Primary reason for rescue
CL Item
Lack of efficacy of study medication (1)
CL Item
Intolerance to study medication (2)
Item Group
Details on Levodopa - rescue therapy
Start Date
Item
Start Date
date
End Date
Item
End Date
date
Total Daily L-dopa Dose
Item
Total Daily L-dopa Dose
float
Proprietary Preparation
Item
Proprietary Preparation
text
Item Group
Adverse Experiences
Ongoing adverse Experiences
Item
Have there been ongoing adverse experiences at the last visit and no adverse experiences occured since?
boolean
Item Group
Details on Adverse Experiences
Experience
Item
Experience
text
For SB
Item
For SB
text
Date Started
Item
Date Started
date
Date Stopped
Item
Date Stopped
date
Duration if less than 24hrs
Item
Duration if less than 24hrs
float
Experience continuing?
Item
Experience continuing?
boolean
Course Continuation
Item
Course Continuation
boolean
If not continuing no. of episodes
Item
If not continuing no. of episodes
integer
Item
Intensity
integer
Code List
Intensity
CL Item
Mild (1)
CL Item
Moderate (2)
CL Item
Severe (3)
Item
Aktion taken on Study Medication
text
Code List
Aktion taken on Study Medication
CL Item
None (1)
CL Item
Dose decreased (2)
CL Item
Dose increased  (3)
CL Item
Drug stopped (4)
CL Item
Dose interrupted (5)
Item
Suspected Relationship
integer
Code List
Suspected Relationship
CL Item
Related (1)
CL Item
Possibly related (2)
CL Item
Possibly unrelated (3)
CL Item
Unrelated (4)
Item
Corrective Therapy
text
Code List
Corrective Therapy
CL Item
Yes (record on Medication form) (1)
CL Item
No (2)
Serious Adverse Experience
Item
Do you consider this a serious adverse experience by the definitions on the tab?
boolean
AEGIS
Item
AEGIS
text
Item Group
Investigator´s Signature
Investigator´s Signature
Item
Investigator´s Signature
text
Date
Item
Date
date
Item Group
Patient Continuation / Withdrawal
Item
Is the patient continuing in the study?
integer
Code List
Is the patient continuing in the study?
CL Item
Yes (1)
CL Item
No (If "No", mark the one most appropriate below, and record the date the patient last took study medication) (2)
Item
Specification of reason for withdrawal
integer
Code List
Specification of reason for withdrawal
CL Item
Adverse experience (complete Adverse Experience section) (1)
CL Item
Lack of Efficacy (2)
CL Item
Deviation from protocol (including non-compliance/protocol violation) (3)
CL Item
Lost to follow-up (4)
CL Item
Other (please specify below) (5)
Specification of other reason for withdrawal
Item
If Other reason for withdrawal, please specify
text
Date of last dose
Item
Date of last dose
date
Item Group
Investigator´s Signature
Investigator´s Signature
Item
Investigator´s Signature
text
Date
Item
Date
date

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial